RecruitingNCT07621237
TNX-102 SL compared with placebo for depression
About this title
Read the official source — NCT07621237Researchers are comparing TNX-102 SL and placebo to find out how the approaches affect depression symptoms in people with depression.
Medication studyAges 18+United States
Understand this study
What is this study about?
Researchers are comparing TNX-102 SL and placebo to find out how the approaches affect depression symptoms in people with depression.
Who could participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
What will I do during this study?
Depending on your group, you take TNX-102 SL or placebo (an inactive comparison treatment) tablets each night at bedtime for six weeks. Clinic checkups and tests are scheduled every two weeks.
- Listed locations
- Phoenix and 26 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 25, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 360
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT07621237
- Official title
Show the full official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Phoenix · Buena Park · Chino
24 more locations
- Lemon Grove
- Orange
- San Diego
- Walnut Creek
- Jacksonville
- Maitland
- Miami
- Orange City
- Orlando
- Tampa
- Norcross
- Chicago
- New Orleans
- Rockville
- Methuen
- Las Vegas
- New York
- North Charleston
- Mephis
- Austin
- Dallas
- McKinney
- Plano
- Provo
Questions about this study
What is this study about?
Researchers are comparing TNX-102 SL and placebo to find out how the approaches affect depression symptoms in people with depression.
Who is behind this study?
The study sponsor is Tonix Pharmaceuticals, Inc.
Does this study involve medication?
Yes. The study involves medication, including TNX-102 SL and Placebo sublingual tablet.
Who can participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
